注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Renalytix plc是一家依托人工智能技术的体外诊断公司。该公司专注于优化肾脏疾病的临床管理,以改善患者预后情况,推动价值性护理。该公司的诊断平台KidneyIntelX旨在扩展糖尿病肾病以外的肾病状况。该公司正在评估慢性肾病、心肾病、不同人群的慢性肾病和冠状病毒病(COVID)相关肾病的一系列新适应症。KidneyIntelX平台通过结合各种数据输入促进数据识别,对面临早期糖尿病肾病(DKD)风险的患者进行有效管理,其数据输入包括包括经过验证的基于血液的生物标志物、遗传基因和来自电子健康记录(HER)的个性化患者数据,再利用专有算法生成独特的患者风险评分。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Christopher Harwood-Bernard Mills | 71 | 2018 | Independent Non-Executive Chairman |
Daniel Joseph Levangie | 73 | 2021 | Independent Non-Executive Director |
Erik K. Lium | 56 | 2018 | Independent Non-Executive Director |
Catherine Coste | 57 | 2023 | Independent Non-Executive Director |
Eugene E. Wright | - | 2023 | Member of Clinical Advisory Board |
Joseph A. Vassalotti | - | 2019 | Member of Clinical Advisory Board |
Barry I. Freedman | - | - | Member of Clinical Advisory Board |
Matthew Jay Budoff | - | 2023 | Member of Clinical Advisory Board |
Javier Morales | - | 2023 | Member of Clinical Advisory Board |
Stephen Brunton | - | 2023 | Member of Clinical Advisory Board |
Ralph A. Defronzo | - | 2023 | Member of Clinical Advisory Board |
Holly J. Mattix-Kramer | - | 2023 | Member of Clinical Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核